schwanderinsurance.com

onbiovc.com

  Every New Beginning… by OnBioBD

http://onbiovc.com/every-new-beginning

Business Development Deal Architecture. Ab – Praluent. Ab – Sarilumab. C – Array BioPharma. C – Celgene. C – Clovis Oncology. C – Ethical Oncology Science. C – Loxo Oncology. C – Novartis. C – Oncothyreon. C – Pfizer. I – Series A. I – Series B. I – Series C. I – Series D. I – Series E. I – Series F. I – Series G. Q – 1Q08. Q – 1Q09. Q – 1Q10. Q – 1Q11. Q – 1Q12. Q – 2Q08. Q – 2Q09. Q – 2Q10. Q – 2Q11. Q – 3Q08. Q – 3Q09. Q – 3Q10. Q – 3Q11. Q – 4Q08. Q – 4Q09. Q – 4Q10. Q – 4Q11. Q – 4Q12. R – WEST.

onbiovc.com

  Kiadis Pharma, B.V.: Series D $12.8M by OnBioBD

http://onbiovc.com/kiadis-pharma-b-v-series-d-12-8m

Business Development Deal Architecture. Ab – Praluent. Ab – Sarilumab. C – Array BioPharma. C – Celgene. C – Clovis Oncology. C – Ethical Oncology Science. C – Loxo Oncology. C – Novartis. C – Oncothyreon. C – Pfizer. I – Series A. I – Series B. I – Series C. I – Series D. I – Series E. I – Series F. I – Series G. Q – 1Q08. Q – 1Q09. Q – 1Q10. Q – 1Q11. Q – 1Q12. Q – 2Q08. Q – 2Q09. Q – 2Q10. Q – 2Q11. Q – 3Q08. Q – 3Q09. Q – 3Q10. Q – 3Q11. Q – 4Q08. Q – 4Q09. Q – 4Q10. Q – 4Q11. Q – 4Q12. R – WEST.

onbiovc.com

  R – NORTH EAST by OnBioBD

http://onbiovc.com/category/x-north-east

Business Development Deal Architecture. Ab – Praluent. Ab – Sarilumab. C – Array BioPharma. C – Celgene. C – Clovis Oncology. C – Ethical Oncology Science. C – Loxo Oncology. C – Novartis. C – Oncothyreon. C – Pfizer. I – Series A. I – Series B. I – Series C. I – Series D. I – Series E. I – Series F. I – Series G. Q – 1Q08. Q – 1Q09. Q – 1Q10. Q – 1Q11. Q – 1Q12. Q – 2Q08. Q – 2Q09. Q – 2Q10. Q – 2Q11. Q – 3Q08. Q – 3Q09. Q – 3Q10. Q – 3Q11. Q – 4Q08. Q – 4Q09. Q – 4Q10. Q – 4Q11. Q – 4Q12. R – WEST.

onbiovc.com

  XX – CA by OnBioBD

http://onbiovc.com/category/xx-ca

Business Development Deal Architecture. Ab – Praluent. Ab – Sarilumab. C – Array BioPharma. C – Celgene. C – Clovis Oncology. C – Ethical Oncology Science. C – Loxo Oncology. C – Novartis. C – Oncothyreon. C – Pfizer. I – Series A. I – Series B. I – Series C. I – Series D. I – Series E. I – Series F. I – Series G. Q – 1Q08. Q – 1Q09. Q – 1Q10. Q – 1Q11. Q – 1Q12. Q – 2Q08. Q – 2Q09. Q – 2Q10. Q – 2Q11. Q – 3Q08. Q – 3Q09. Q – 3Q10. Q – 3Q11. Q – 4Q08. Q – 4Q09. Q – 4Q10. Q – 4Q11. Q – 4Q12. R – WEST.

onbiovc.com

  I – Series F by OnBioBD

http://onbiovc.com/category/series-f

Business Development Deal Architecture. Ab – Praluent. Ab – Sarilumab. C – Array BioPharma. C – Celgene. C – Clovis Oncology. C – Ethical Oncology Science. C – Loxo Oncology. C – Novartis. C – Oncothyreon. C – Pfizer. I – Series A. I – Series B. I – Series C. I – Series D. I – Series E. I – Series F. I – Series G. Q – 1Q08. Q – 1Q09. Q – 1Q10. Q – 1Q11. Q – 1Q12. Q – 2Q08. Q – 2Q09. Q – 2Q10. Q – 2Q11. Q – 3Q08. Q – 3Q09. Q – 3Q10. Q – 3Q11. Q – 4Q08. Q – 4Q09. Q – 4Q10. Q – 4Q11. Q – 4Q12. R – WEST.

onbiovc.com

  X – Pain by OnBioBD

http://onbiovc.com/category/xx-pain

Business Development Deal Architecture. Ab – Praluent. Ab – Sarilumab. C – Array BioPharma. C – Celgene. C – Clovis Oncology. C – Ethical Oncology Science. C – Loxo Oncology. C – Novartis. C – Oncothyreon. C – Pfizer. I – Series A. I – Series B. I – Series C. I – Series D. I – Series E. I – Series F. I – Series G. Q – 1Q08. Q – 1Q09. Q – 1Q10. Q – 1Q11. Q – 1Q12. Q – 2Q08. Q – 2Q09. Q – 2Q10. Q – 2Q11. Q – 3Q08. Q – 3Q09. Q – 3Q10. Q – 3Q11. Q – 4Q08. Q – 4Q09. Q – 4Q10. Q – 4Q11. Q – 4Q12. R – WEST.

onbiovc.com

  Uncategorized by OnBioBD

http://onbiovc.com/category/uncategorized

Business Development Deal Architecture. Ab – Praluent. Ab – Sarilumab. C – Array BioPharma. C – Celgene. C – Clovis Oncology. C – Ethical Oncology Science. C – Loxo Oncology. C – Novartis. C – Oncothyreon. C – Pfizer. I – Series A. I – Series B. I – Series C. I – Series D. I – Series E. I – Series F. I – Series G. Q – 1Q08. Q – 1Q09. Q – 1Q10. Q – 1Q11. Q – 1Q12. Q – 2Q08. Q – 2Q09. Q – 2Q10. Q – 2Q11. Q – 3Q08. Q – 3Q09. Q – 3Q10. Q – 3Q11. Q – 4Q08. Q – 4Q09. Q – 4Q10. Q – 4Q11. Q – 4Q12. R – WEST.

onbiovc.com

  I – Series A by OnBioBD

http://onbiovc.com/category/series-a

Business Development Deal Architecture. Ab – Praluent. Ab – Sarilumab. C – Array BioPharma. C – Celgene. C – Clovis Oncology. C – Ethical Oncology Science. C – Loxo Oncology. C – Novartis. C – Oncothyreon. C – Pfizer. I – Series A. I – Series B. I – Series C. I – Series D. I – Series E. I – Series F. I – Series G. Q – 1Q08. Q – 1Q09. Q – 1Q10. Q – 1Q11. Q – 1Q12. Q – 2Q08. Q – 2Q09. Q – 2Q10. Q – 2Q11. Q – 3Q08. Q – 3Q09. Q – 3Q10. Q – 3Q11. Q – 4Q08. Q – 4Q09. Q – 4Q10. Q – 4Q11. Q – 4Q12. R – WEST.

onbiovc.com

  X – Mitochondrial by OnBioBD

http://onbiovc.com/category/x-mitochondrial

Business Development Deal Architecture. Ab – Praluent. Ab – Sarilumab. C – Array BioPharma. C – Celgene. C – Clovis Oncology. C – Ethical Oncology Science. C – Loxo Oncology. C – Novartis. C – Oncothyreon. C – Pfizer. I – Series A. I – Series B. I – Series C. I – Series D. I – Series E. I – Series F. I – Series G. Q – 1Q08. Q – 1Q09. Q – 1Q10. Q – 1Q11. Q – 1Q12. Q – 2Q08. Q – 2Q09. Q – 2Q10. Q – 2Q11. Q – 3Q08. Q – 3Q09. Q – 3Q10. Q – 3Q11. Q – 4Q08. Q – 4Q09. Q – 4Q10. Q – 4Q11. Q – 4Q12. R – WEST.

onbiovc.com

  R – WEST by OnBioBD

http://onbiovc.com/category/x-west

Business Development Deal Architecture. Ab – Praluent. Ab – Sarilumab. C – Array BioPharma. C – Celgene. C – Clovis Oncology. C – Ethical Oncology Science. C – Loxo Oncology. C – Novartis. C – Oncothyreon. C – Pfizer. I – Series A. I – Series B. I – Series C. I – Series D. I – Series E. I – Series F. I – Series G. Q – 1Q08. Q – 1Q09. Q – 1Q10. Q – 1Q11. Q – 1Q12. Q – 2Q08. Q – 2Q09. Q – 2Q10. Q – 2Q11. Q – 3Q08. Q – 3Q09. Q – 3Q10. Q – 3Q11. Q – 4Q08. Q – 4Q09. Q – 4Q10. Q – 4Q11. Q – 4Q12. R – WEST.